TRANSPERS to build registry that will shed light on payers’ payment policies for new genetic tests
New genetic testing panels and sequencing-based tests have the potential to transform healthcare. However, little is known about whether payers and insurers will pay for these tests. TRANSPERS has received a grant from the National Human Genome Research Institute to develop a registry of public and payer coverage policies for new and emerging genetic tests. We will use this registry to systematically track who is or will be paying for new genetic tests as well as the factors that determine coverage. Our registry will build on the highly successful Tufts Medical Center Cost-Effectiveness Analysis Registry and will be developed by reimbursement experts. This work will be guided by an advisory group that includes a broad range of stakeholders — clinicians, public insurers, laboratories, industry, professional organizations, government, and technology assessment groups.